Carboplatin shortage — US supply status & alternatives

Carboplatin

ATC L01XA02

🇦🇺 AUST R 12880 · Pfizer Australia Pty Ltd

In supply · Australia

WHO Essential Medicine

EugiaCarboplatino AhclCarboplatino Accord

In supply · 🇦🇺 Australia · short in🇺🇸 US🇨🇦 CA🇧🇪 BE

In supply in Australia

Reading today’s signals…

🇦🇺 AUAEMPA$30.00details →

✓ Can I substitute?

Per normal rules

Confirm with prescriber

⇄ Best alternative

Carboplatino

Expected back

No estimate provided

Product attributes reference data we hold

Active ingredient (INN)	Carboplatin
Brand names	Eugia, Carboplatino Ahcl, Carboplatino Accord
ATC level 5	L01XA02
ATC level 4	L01XA
Therapeutic category	Auto-created by Therapeutic Goods Administration — Medicine Shortages scraper
WHO Essential Medicine	Yes (2023)
Controlled substance	No
Marketing-authorisation holders	TEVA UK LIMITED, Hospira UK Limited, FRESENIUS KABI LIMITED, EBEWE PHARMA GES.M.B.H NFG. KG +6 more
Registrations on file	19
Patient information leaflet (PIL)	Not on file
Summary of product characteristics (SPC)	Not on file

Trade price 🇦🇺 PBS · July 2026

🇦🇺 AU

● Official price on file

Ex-manufacturer

A$30.00

AEMP

Dispensed (DPMQ)

—

incl. fees

Pack

carboplatin 450 mg/45 mL injection, 45 mL vial

Source: PBSEffective July 2026 · AUD

Substitution pathways 🇦🇺 Australia · TGA

—

No substitution instrument in force

Dispense per normal rules, or refer to the prescriber. No active SSSI/S19A instrument detected for this medicine.

How long have past shortages lasted? from 1 resolved event

◷

~4 months

Historical pattern from resolved shortage records — not a prediction of this event.

Global API supply base 🇺🇸 FDA Drug Master Files · active Type II

10 API manufacturers

Manufacturers with an active Type II Drug Master File — i.e. cleared to supply this active ingredient into the US market. A proxy for how concentrated the global manufacturing base is.

Low concentration risk

Umicore Argentina SALaurus Labs LTDVeranova LPHeraeus Precious Metals GMBH And CO KgStrem Chemicals INCSun Pharmaceutical Industries LTD+4 more

Manufacturing countries: Argentina, India, United States, Germany, China · Source: FDA List of Drug Master Files

FDA-approved products 🇺🇸 Drugs@FDA

Approved applications

Generic (ANDA)

Brand (NDA/BLA)

Feb 2026

Latest approval

Shortage status by regulator official notices

🇺🇸

United States

FDA · 2h ago

Critical

🇨🇦

Canada

HC · 2h ago

High

🇧🇪

FAMHP · 3h ago

Medium

🇦🇺

Australia

TGA · 3mo ago

Resolved

Recalls official enforcement reports

🇺🇸

Carboplatin

Infusion Options, Inc. · June 2019

Class IIdetails ↗

🇺🇸

CARBOPLATIN

Hospira Inc. · Nov 2012

Class Idetails ↗

🇺🇸

CARBOPLATIN

Hospira Inc. · Nov 2012

Class Idetails ↗

🇺🇸

CARBOPLATIN

Hospira Inc. · July 2012

Class IIIdetails ↗

🇺🇸

CARBOPLATIN

Hospira Inc. · June 2012

Class IIdetails ↗

Verified timeline regulator events

🇺🇸 1 June 2026

medium reported

🇧🇪 10 Mar 2026

medium reported

🇺🇸 20 Feb 2026

medium reported

🇺🇸 20 Feb 2026

medium reported

🇦🇺 14 Aug 2025

Shortage resolved

🇺🇸 28 Mar 2025

medium reported

Sources official regulators

🇨🇦

verified 2h ago

verify ↗

🇺🇸

FDA

verified 2h ago

verify ↗

🇧🇪

FAMHP

verified 3h ago

verify ↗

🇦🇺

TGA

verified 3mo ago

verify ↗

Registration recordmarketing-authorisation holders

Registrations & marketing-authorisation holders19 registrations · 10 MA holders

Product	Strength	Form	Market	MA holder	Status
Carboplatin Concentrate For Infusion	10MG	infusion	🇬🇧 GB	TEVA UK LIMITED	Active
CARBOPLATIN INJECTION SOLUTION 10MG PER ML	10MG	injection	🇬🇧 GB	Hospira UK Limited	Active
CARBOPLATIN 10 MG/ML CONCENTRATE FOR SOLUTION FOR INFUSION	10 MG	solution	🇬🇧 GB	FRESENIUS KABI LIMITED	Active
CARBOPLATIN 10MG/ML CONCENTRATE FOR SOLUTION FOR INJ BP	10MG	solution	🇬🇧 GB	EBEWE PHARMA GES.M.B.H NFG. KG	Active
CARBOPLATIN 10 MG/ML SOLUTION FOR INFUSION	10 MG	solution	🇬🇧 GB	HIKMA FARMACEUTICA (PORTUGAL) SA	Active
Carboplatin Venus Pharma	10 MG	solution	🇬🇧 GB	VENUS PHARMA GMBH	Active
CARBOPLATIN 10MG/ML CONCENTRATE FOR SOLUTION FOR INFUSION	10MG	solution	🇬🇧 GB	EUGIA (UK) LIMITED	Active
Dbl Carboplatin	50mg	—	🇦🇺 AU	Pfizer Australia Pty Ltd	Active
Pfizer	50 mg	—	🇦🇺 AU	Pfizer Australia Pty Ltd	Active
Dbl Carboplatin	150mg	—	🇦🇺 AU	Pfizer Australia Pty Ltd	Active
Dbl Carboplatin	450mg	—	🇦🇺 AU	Pfizer Australia Pty Ltd	Active
Pfizer	150 mg	—	🇦🇺 AU	Pfizer Australia Pty Ltd	Active
Pfizer	450 mg	—	🇦🇺 AU	Pfizer Australia Pty Ltd	Active
Kabi	450mg	—	🇦🇺 AU	Fresenius Kabi Australia Pty Ltd	Active
Kabi	150mg	—	🇦🇺 AU	Fresenius Kabi Australia Pty Ltd	Active

+4 more registrations on file

Mederti Drug Report

Generated 1 July 2026 · Australia market · 4 regulatory sources

For health-professional reference only. Mederti aggregates shortage and substitution information from official regulatory sources. It is not clinical advice and data may be incomplete or delayed. Confirm any substitution or supply decision against the primary regulator source, the prescriber, and current clinical references (e.g. AMH) before acting. Terms.